All In Biotech

Drug Trial Radar · NCT05679258

A Study to Compare the PK , Safety, Tolerability, and Immunogenicity of HLX15 With Daratumumab in Male Subjects

A Phase I Study to Compare the Pharmacokinetic Characteristics, Safety, Tolerability, and Immunogenicity (Randomized, Double-blind, Parallel Controlled) of HLX15 With Daratumumab Injection in Healthy Chinese Male Subjects

Last checked: Nov 19, 2026Latest source record: Jun 28, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 172 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

172

Actual

Start

Jan 31, 2023

Primary completion

Mar 16, 2024

Study completion Jun 28, 2024

Sponsor

Lead sponsor
Shanghai Henlius BiotechIndustry
Sponsor type
Industry
First posted
Jan 10, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
Male only, from 18 years, up to 60 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

Phase I Study to Compare the Pharmacokinetic Characteristics, Safety, Tolerability, and Immunogenicity (Randomized, Double-blind, Parallel Controlled) of HLX15 with Daratumumab Injection in Healthy Chinese Male Subjects

Conditions

  • Multiple Myeloma

Interventions

  • HLX15Drug

    A single dose (8 mg/kg) of HLX15 via intravenous infusion.

  • US-sourced DARZALEX®Drug

    A single dose (8 mg/kg) of US-sourced DARZALEX® via intravenous infusion.

  • CN-sourced DARZALEX®Drug

    A single dose (8 mg/kg) of CN-sourced DARZALEX® via intravenous infusion.

  • EU-sourced DARZALEX®Drug

    A single dose (8 mg/kg) of EU-sourced DARZALEX® via intravenous infusion.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Area under the serum concentration-time curve from time 0 to infinity (AUC0-inf).Time frame: Up to Day 91

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Beijing Hospital

    Beijing, Beijing Municipality, China

  • Sir Run Run Hospital, Nanjing Medical University

    Nanjing, Jiangsu, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.